ONC206

Catalog No.S6853

For research use only.

ONC206 is a selective antagonist of dopamine D2-like receptors (DRD2/3/4) with broad-spectrum anti-tumor activity.

ONC206 Chemical Structure

CAS No. 1638178-87-6

Purity & Quality Control

Choose Selective Dopamine Receptor Inhibitors

Other Dopamine Receptor Products

Biological Activity

Description ONC206 is a selective antagonist of dopamine D2-like receptors (DRD2/3/4) with broad-spectrum anti-tumor activity.
Targets
DRD2 [1]
()

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 82 mg/mL
(200.76 mM)
Water Insoluble
Ethanol '27 mg/mL

Chemical Information

Molecular Weight 408.44
Formula

C23H22F2N4O

CAS No. 1638178-87-6
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04732065 Recruiting Drug: ONC206|Radiation: Standard of Care Radiation Therapy Diffuse Midline Glioma (DMG)|Malignant Brain Tumors|Glioblastoma|Recurrent Ependymoma|Recurrent Malignant Brain Neoplasm|Spinal Cord Glioma|WHO Grade III Glioma Sabine Mueller MD PhD|Chimerix|Mithil Prasad Foundation|Storm the Heavens Fund|The ChadTough Defeat DIPG Foundation|University of California San Francisco August 23 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy ONC206 | ONC206 supplier | purchase ONC206 | ONC206 cost | ONC206 manufacturer | order ONC206 | ONC206 distributor